ArticlePloS one2018
Novel coronavirus-like particles targeting cells lining the respiratory tract.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Recent Advances in Antiviral Drug Delivery Strategies.AAPS PharmSciTech · 2025Review
- Rapid and Scalable Production of Functional SARS-CoV-2 Virus-like Particles (VLPs) by a Stable HEK293 Cell Pool.Vaccines · 2024Article
- Molecular mechanisms of human coronavirus NL63 infection and replication.Virus research · 2023Review
- Stability of SARS-CoV-2 in cold-chain transportation environments and the efficacy of disinfection measures.Frontiers in cellular and infection microbiology · 2023Article
- Review
- Review
- Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms.Molecular biology reports · 2022Review
- Immunotherapeutic nanoparticles: From autoimmune disease control to the development of vaccines.Biomaterials advances · 2022Review
- Recent and advanced nano-technological strategies for COVID-19 vaccine development.Methods in microbiology · 2022Article
- Genetic Engineering Systems to Study Human Viral Pathogens from the Coronaviridae Family.Molecular biology · 2022Article
- Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-2.Journal of controlled release : official journal of the Controlled Release Society · 2021Review
- PRAK-03202: A triple antigen virus-like particle vaccine candidate against SARS CoV-2.Heliyon · 2021Article
- Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms.International immunopharmacology · 2021Review
- COVID-19 immunity and vaccines: what a pharmacist needs to know.Asian biomedicine : research, reviews and news · 2021Review
- The role of nanotechnology in current COVID-19 outbreak.Heliyon · 2021Review
- Functional Severe Acute Respiratory Syndrome Coronavirus 2 Virus-Like Particles From Insect Cells.Frontiers in microbiology · 2021Article
- Nanomedicine strategies to target coronavirus.Nano today · 2020Review
- Kallikrein 13 serves as a priming protease during infection by the human coronavirus HKU1.Science signaling · 2020Article
- Immunological considerations for COVID-19 vaccine strategies.Nature reviews. Immunology · 2020Review
- Replication of Severe Acute Respiratory Syndrome Coronavirus 2 in Human Respiratory Epithelium.Journal of virology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Virus like particles (VLPs) produced by the expression of viral structural proteins can serve as versatile nanovectors or potential vaccine candidates. In this study we describe for the first time the generation of HCoV-NL63 VLPs using baculovirus system. Major structural proteins of HCoV-NL63 have been expressed in tagged or native form, and their assembly to form VLPs was evaluated. Additionally, a novel procedure for chromatography purification of HCoV-NL63 VLPs was developed. Interestingly, we show that these nanoparticles may deliver cargo and selectively transduce cells expressing the ACE2 protein such as ciliated cells of the respiratory tract. Production of a specific delivery vector is a major challenge for research concerning targeting molecules. The obtained results show that HCoV-NL63 VLPs may be efficiently produced, purified, modified and serve as a delivery platform. This study constitutes an important basis for further development of a promising viral vector displaying narrow tissue tropism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.